How Does Parkinson’s Prevalence Differ in High-Income Versus Low-Income Countries, What Percentage Are Affected, and How Do Treatment Access Levels Compare? 🌍🧠💊

This article is written by mr.hotsia, a long term traveler and storyteller who runs a YouTube travel channel followed by over a million followers. Over the years he has crossed borders and backroads throughout Thailand, Laos, Vietnam, Cambodia, Myanmar, India and many other Asian countries, sleeping in small guesthouses, village homes and roadside inns. Along the way he has listened to real life health stories from locals, watched how people actually live day to day, and collected simple lifestyle ideas that may help support better wellbeing in practical, realistic ways.

When people ask whether Parkinson’s disease is more common in rich countries than in poorer countries, the answer is yes in many datasets, but the story is not as simple as money alone. Higher-income settings often report higher measured prevalence, but that can reflect several things happening at once: longer life expectancy, older populations, better diagnosis, better recording of disease, and longer survival after diagnosis. Lower-income settings may look lighter on the map partly because the disease is truly less often diagnosed and less often counted, not necessarily because it is genuinely rare. Recent global reviews make this point very clearly. Parkinson’s burden is rising everywhere, but the visibility of that burden depends heavily on health system strength.

A useful modern way to compare countries is through SDI, or Socio-demographic Index, because many of the best global Parkinson’s analyses report burden that way rather than by simple World Bank income category. In those analyses, higher-development settings generally show higher measured age-standardized prevalence. In one 2025 global burden study, the age-standardized prevalence in 2021 was 125.17 per 100,000 in high-SDI countries and 72.87 per 100,000 in low-SDI countries. In plain percentages, that is about 0.125% versus 0.073%. Interestingly, the highest prevalence was not in the very highest SDI tier, but in the high-middle SDI tier at 173.39 per 100,000, or about 0.173%. That tells us Parkinson’s is not merely a “rich country disease.” It is a global disease whose recorded burden rises with demographic transition, urbanization, and better detection.

So if someone wants the simplest possible comparison, the answer is this: measured Parkinson’s prevalence is generally higher in more developed settings, with global burden studies suggesting roughly 0.125% in high-SDI settings versus about 0.073% in low-SDI settings, while some middle and high-middle settings now exceed both. But those numbers should be read carefully. They describe what is measured, not necessarily the full hidden burden.

Why higher-income countries often show higher prevalence

At first glance, it might seem natural to assume that higher prevalence in wealthier countries means wealth somehow causes Parkinson’s. That is not the right conclusion. A much better explanation is that high-income settings usually have more of the ingredients that make Parkinson’s visible. People live longer, and Parkinson’s is strongly age-related. Primary care systems and neurologists are more available. Brain imaging and specialist review are easier to access. Patients survive longer with treatment, which raises prevalence because more people are living with the disease at any given moment. The 2024 meta-analysis focused on lower- to upper-middle-income countries also found greater prevalence in populations with higher five-year GDP per capita and higher life expectancy, again pointing toward the role of development and longevity.

Lower-income countries often face the opposite problem. WHO states plainly that levodopa/carbidopa, the most effective drug for improving symptoms, functioning, and quality of life, is not accessible, available, or affordable everywhere, especially in low- and middle-income countries. WHO also notes that many medications and surgical resources remain inaccessible in these settings. When specialist diagnosis, treatment, and follow-up are weak, prevalence can be underestimated because fewer people ever receive a formal diagnosis in the first place.

This is why low measured prevalence can be deceptive. In low-resource settings, the true burden may be partly hidden behind underdiagnosis, delayed diagnosis, stigma, and limited service capacity. A recent Thailand-focused review warned that many early-stage cases in low- and middle-income settings remain undiagnosed during the period when intervention would have the most value and lowest cost.

What percentage are affected in high-income versus low-income settings?

Because different studies use different methods, there is no single perfect pair of percentages for every rich and poor country in the world. Still, the best global burden estimates give a helpful working picture.

Using SDI as the closest global proxy for income level, the 2021 age-standardized prevalence figures were:

High SDI: 125.17 per 100,000, which is about 0.125%
Low SDI: 72.87 per 100,000, which is about 0.073%
High-middle SDI: 173.39 per 100,000, which is about 0.173%
Low-middle SDI: 91.89 per 100,000, which is about 0.092%
Middle SDI: 154.79 per 100,000, which is about 0.155%

Those numbers tell an important story. The burden is not flat. It tends to rise as countries move through demographic and economic transition, but the highest observed burden can sit in high-middle rather than strictly high-income settings. That may reflect a combination of aging populations, rising environmental exposures, and improving case detection in countries moving rapidly through development.

So if you compare a typical high-income setting with a low-income one using the best global standardized numbers, the difference is roughly 0.125% versus 0.073%. In practical terms, that means the measured burden in the high-SDI group is about 1.7 times the low-SDI group. But again, that gap should not be read as pure biology. It is heavily shaped by who gets counted and how long they live with the condition.

Why low-income countries may be more affected than the raw percentages suggest

A 2025 burden analysis summarized a growing concern in the field by saying inequalities in Parkinson’s burden between high- and low-income areas have widened, with low-income regions becoming more affected over time. That sounds at first like it contradicts the lower prevalence figures, but it really reflects a deeper truth. Burden is not only about prevalence. It is also about disability, delayed diagnosis, poor treatment access, and avoidable suffering. A lower recorded prevalence can coexist with worse real-world burden if people are diagnosed late, undertreated, or never treated at all.

WHO’s recent policy material on Parkinson’s medicines in the African Region states that health systems in many low- and middle-income countries are not prepared to diagnose and manage Parkinson’s, partly because of the lack of specialist neurological services. The same source says that large proportions of the population remain without access to treatment. That means the disease may be less visible in surveillance data while being more devastating in lived experience.

How do treatment access levels compare?

This is the part where the contrast between richer and poorer settings becomes especially sharp.

A 2022 global survey of Parkinson’s treatment availability found that fully government-funded Parkinson’s medication dropped steeply as country income decreased: 50.0% in high-income countries, 33.6% in upper-middle-income countries, and only 3.0% in lower-middle-income and low-income countries. That is not a small difference. It is a cliff edge.

The same global survey found major gaps in allied health services too. Occupational therapy availability was 80.1% in high-income countries versus 49.5% in lower-middle-income and low-income countries. Speech and language therapy was available in 84.9% of high-income settings versus 55.6% in lower-middle-income and low-income settings. Physiotherapy was more widely available than other therapies, but even there the broader pattern was still inequality by income.

These differences matter because Parkinson’s care is not only about tablets. A patient may need gait training, speech therapy, swallowing support, occupational therapy, mental health care, and later advanced therapies. When those services are missing, the disease becomes more disabling even if a diagnosis has technically been made.

The medicine gap in lower-income countries

The African data are especially striking. A 2024 qualitative study from Kenya states that poor accessibility of Parkinson’s medicines, including levodopa/carbidopa, remains a major challenge across sub-Saharan Africa. It cites the WHO Neurology Atlas finding that only 3% of countries in the WHO African Region had levodopa/carbidopa always available at the primary care level. In those settings, medicine is often paid for out of pocket because insurance coverage is weak.

WHO’s fact sheet echoes this broader pattern by stating that levodopa/carbidopa is not accessible, available, or affordable everywhere, especially in low- and middle-income countries. WHO also notes that rehabilitation can improve function and quality of life, yet many of these supportive services remain out of reach in lower-resource settings.

So when comparing treatment access levels, the broad contrast is this: in high-income countries, treatment is more likely to be funded, specialists are more likely to be available, and allied therapies are more likely to exist as part of routine care. In lower-income countries, even core medication access can be unreliable, and supportive therapies are often patchy or absent.

Specialist access and diagnosis

Another important difference is who can actually diagnose Parkinson’s. In high-income countries, a patient is much more likely to reach a neurologist or movement disorders specialist, either directly or after referral. In lower-income settings, WHO notes that diagnosis often needs to be shifted toward trained non-specialist healthcare workers and simplified treatment guidelines because specialist services are scarce. That statement alone shows how differently care systems are organized across income levels.

This is not necessarily bad in principle. Training non-specialists is often a sensible and necessary strategy. But it also reveals the size of the workforce gap. Where neurologists are few, diagnosis is slower, misdiagnosis is more likely, and advanced therapies such as deep brain stimulation, infusion therapies, or multidisciplinary rehabilitation are far less reachable.

Why the treatment gap changes outcomes

In richer settings, a patient with Parkinson’s is more likely to receive medication earlier, get dose adjustments on time, access physiotherapy and speech therapy, and be considered for advanced care if symptoms become complicated. In poorer settings, the disease often progresses in a thinner net. A person may wait longer for diagnosis, pay cash for medication, interrupt treatment because of cost or supply, and never meet the kinds of specialists who might optimize care.

This gap changes more than convenience. It changes function, independence, work ability, caregiver burden, and avoidable disability. WHO emphasizes that effective medicines and therapies can improve functioning and quality of life. So when those tools are not available, the burden of Parkinson’s becomes heavier even if the raw prevalence number looks smaller.

Does this mean high-income countries are “worse” for Parkinson’s?

Not exactly. They often record more cases and show higher measured prevalence, but they also usually offer better survival and better care. Low-income countries may record fewer cases while leaving more of the disease untreated. That is why prevalence and suffering do not move in perfect lockstep.

A useful way to think about it is this. High-income countries often have brighter lanterns and wider treatment roads. Low-income countries may have dimmer lanterns and rougher roads. The first landscape shows more of the disease because it is easier to see and people live longer with it. The second landscape may show less on paper while carrying more hidden burden in real life.

The bottom line

Parkinson’s disease is generally measured more often in high-income or high-SDI settings than in low-income ones, with 2021 global burden estimates suggesting about 0.125% prevalence in high-SDI countries versus about 0.073% in low-SDI countries. High-middle SDI settings actually showed the highest age-standardized prevalence at about 0.173%, showing that the burden is rising strongly outside the richest countries too.

Treatment access differs even more sharply than prevalence. In a global treatment survey, fully government-funded Parkinson’s medication was reported in 50.0% of high-income countries, 33.6% of upper-middle-income countries, and only 3.0% of lower-middle-income and low-income countries. Occupational therapy and speech therapy were also much more available in high-income settings than in poorer ones.

So the simplest answer is this: richer countries usually show more Parkinson’s on paper, but poorer countries often face a harsher treatment gap. One side has higher visibility. The other often has deeper invisibility and thinner care.

FAQs

1. Is Parkinson’s more common in high-income countries?

Measured prevalence is usually higher in high-income or higher-SDI settings, but part of that difference likely reflects better diagnosis, older populations, and longer survival.

2. What percentage are affected in high-income versus low-income settings?

Using SDI as a global proxy, age-standardized prevalence in 2021 was about 0.125% in high-SDI countries and 0.073% in low-SDI countries.

3. Which development group had the highest prevalence?

In one 2025 global burden analysis, the high-middle SDI group had the highest age-standardized prevalence at 173.39 per 100,000, or about 0.173%.

4. Why can low-income countries show lower prevalence even if the burden is serious?

Because lower diagnosis rates, fewer specialists, stigma, and weak disease recording can all hide the true burden.

5. Is levodopa available everywhere?

No. WHO states that levodopa/carbidopa is not accessible, available, or affordable everywhere, especially in low- and middle-income countries.

6. How big is the funding gap for Parkinson’s medication?

A global survey found fully government-funded Parkinson’s medication in 50.0% of high-income countries, 33.6% of upper-middle-income countries, and only 3.0% of lower-middle-income and low-income countries.

7. Are rehabilitation services also less available in poorer countries?

Yes. Occupational therapy and speech-language therapy were reported much less often in lower-middle-income and low-income settings than in high-income settings.

8. What is one striking example from Africa?

In the WHO African Region, only 3% of countries were reported to have levodopa/carbidopa always available at the primary care level.

9. Do lower-income countries need specialists only?

Not only specialists. WHO also emphasizes training non-specialized healthcare workers and using simplified treatment guidelines to improve management where specialist services are scarce.

10. What is the simplest way to understand the global difference?

High-income countries often count more Parkinson’s because they can see and treat it better. Low-income countries often count less while struggling more to diagnose and support the people who have it.

I’m Mr.Hotsia, sharing 30 years of travel experiences with readers worldwide. This review is based on my personal journey and what I’ve learned along the way. Learn more